Showing results (1-10 of 288) with videos related to
Sort By:
Pageof 29
Therapeutic Advances in Musculoskeletal Disease|October 18, 2021
The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritisAli Berkant Avci, Eugen Feist, Gerd Rüdiger BurmesterBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2018
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?Ali Berkant Avci, Eugen Feist, Gerd Rüdiger BurmesterClinical and Experimental Rheumatology|September 3, 2016
Targeting GM-CSF in rheumatoid arthritisAli Berkant Avci, Eugen Feist, Gerd-Rüdiger BurmesterRheumatology (Oxford, England)|May 5, 2021
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritisAli Berkant Avci, Eugen Feist, Gerd Rüdiger BurmesterClinical Immunology (Orlando, Fla.)|August 1, 2016
The proteasome - victim or culprit in autoimmunityEugen Feist, Gerd-Rüdiger Burmester, Elke KrügerDeutsches Arzteblatt International|July 7, 2009
The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigensKarl Egerer, Eugen Feist, Gerd-Rüdiger BurmesterRheumatology (Oxford, England)|February 21, 2025
Rheumatoid factors revisited in the age of biologic therapyAli Berkant Avci, Eugen Feist, Gerd R BurmesterBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 22, 2023
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?Ali Berkant Avci, Eugen Feist, Gerd R BurmesterRMD Open|November 5, 2015
Biologicals in rheumatoid arthritis: current and futureAli Berkant Avci, Eugen Feist, Gerd-R BurmesterRMD Open|August 30, 2017
Automated evaluation of ANA under real-life conditionsClemens Dario Loock, Karl Egerer, Eugen Feist, et al.Pageof 29